Dronedarone is an
amiodarone-like
antiarrhythmic drug associated with severe liver injury. Since
dronedarone inhibits mitochondrial respiration and β-oxidation in vitro, mitochondrial toxicity may also explain
dronedarone-associated hepatotoxicity in vivo. We therefore studied hepatotoxicity of
dronedarone (200mg/kg/day for 2 weeks or 400mg/kg/day for 1 week by intragastric gavage) in heterozygous juvenile
visceral steatosis (jvs(+/-)) and wild-type mice. Jvs(+/-) mice have reduced
carnitine stores and are sensitive for mitochondrial β-oxidation inhibitors. Treatment with
dronedarone 200mg/kg/day had no effect on
body weight, serum
transaminases and
bilirubin, and hepatic mitochondrial function in both wild-type and jvs(+/-) mice. In contrast,
dronedarone 400mg/kg/day was associated with
a 10-15% drop in
body weight, and a 3-5-fold increase in
transaminases and
bilirubin in wild-type mice and, more accentuated, in jvs(+/-) mice. In vivo metabolism of intraperitoneal (14)C-palmitate was impaired in wild-type, and, more accentuated, in jvs(+/-) mice treated with 400mg/kg/day
dronedarone compared to vehicle-treated mice. Impaired β-oxidation was also found in isolated mitochondria ex vivo. A likely explanation for these findings was a reduced activity of
carnitine palmitoyltransferase 1a in liver mitochondria from
dronedarone-treated mice. In contrast,
dronedarone did not affect the activity of the respiratory chain ex vivo. We conclude that
dronedarone inhibits mitochondrial β-oxidation in and ex vivo, but not the respiratory chain. Jvs(+/-) mice are slightly more sensitive for the effect of
dronedarone on mitochondrial β-oxidation than wild-type mice. The results suggest that inhibition of mitochondrial β-oxidation is an important mechanism of hepatotoxicity associated with
dronedarone.